Mobiquity Contributes to Design and Development of First U.S. FDA-Approved Digital Medicine System
WALTHAM, Mass. (PRWEB) December 04, 2017 -- For Mobiquity, the digital engagement provider that contributed to the design and development of ABILIFY MYCITE®, the first U.S. Food and Drug Administration (FDA)-approved digital medicine system, news of the FDA approval granted to Otsuka Pharmaceutical Co., Ltd. (Otsuka) marks an important milestone in its journey of innovation and a digital first in drug development.
ABILIFY MYCITE (aripiprazole tablets with sensor) is a drug-device combination product comprised of Otsuka’s oral aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor. The ABILIFY MYCITE System (http://www.abilifymycite.com) includes: ABILIFY MYCITE, the MYCITE® Patch (wearable sensor); the MYCITE APP (a smartphone application); and web-based portals for healthcare providers and caregivers. Mobiquity designed and developed the patient app as well as the healthcare provider and caregiver portals for patient support.
Mobiquity assembled a global team of designers, engineers, and healthcare experts to successfully deliver these products. In doing so, the team designed and built the overall mobile architecture, a secure, HIPAA-compliant hosting solution, custom human factors tools, and human training tools for product demonstration and support. The Mobiquity team also provided advanced technical support for clinical studies in addition to collaborating on testing and validation.
“It has been a long and fulfilling journey of innovation in reaching this digital first, but one that is now just getting started,” said John Castleman, CEO of Mobiquity. “We are committed to working with our clients to help them advance and evolve quality care through uncovering new ways to connect patients to the information and expertise they need.”
“I think what this will do is usher in an era of collaboration amongst the physician, the patient, their family, and their care team,” said Andrew Wright, VP of Digital Medicine at Otsuka, in a recent MobiHealthNews article.* “We think this will lead to a more informed discussion rather than the assumption that the patient is taking their medication, and that can lead to a better understanding of the reasons for not taking it.”
Mobiquity’s contributions to the ABILIFY MYCITE System reflect the company’s ongoing effort to help leading healthcare and life sciences brands in engaging patients beyond the pill with digital solutions to support continuous care across a variety of therapeutic areas.
About Mobiquity
Mobiquity Inc. is a digital engagement innovator helping the world’s leading brands reach and realize their best futures. Digital born and business bred, the company infuses innovative intuition into an evolving array of apps, actions, and interactions to engage patients, consumers, employees, and publics at deeper levels and in new ways.
Founded in 2011, the company employs more than 450 people collaborating across three continents.
Combining strategy, human-centered research, experience design, product engineering, and analytics, Mobiquity is pioneering a path of digital firsts across all industries, including healthcare, life sciences, consumer products, financial services, hospitality, media, and entertainment. To learn more, visit http://www.mobiquityinc.com.
*Comstock, Jonah. “In-Depth: How digital sensors could change the face of pharma.” MobiHealthNews 17 November 2017 http://www.mobihealthnews.com/content/depth-how-digital-sensors-could-change-face-pharma
Sydney Fenkell, Mobiquity, http://mobiquityinc.com/, +1 (781) 591-4800, [email protected]
Share this article